AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30896297 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia Catastrophizing Scale (ICS) - daytime catastrophizing subscale (6 items)
Number of subjects: 1615
Study 30896297 — intervention group
Group type: COMPARATOR
Intervention: Insomnia disorder group
Number of subjects: 1615
Study 30896297 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS subscales
Number of subjects: 1615
Study 30485450 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanguisorba officinalis root extract
Number of subjects: 21
Study 30485450 — intervention group
Group type: COMPARATOR
Intervention: Placebo formulation
Number of subjects: 21
Study 27802242 — intervention group
Group type: EXPERIMENTAL
Intervention: Safinamide 100 mg/day
Number of subjects: 0
Study 27802242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26314432 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenous acid (H3AsO3) treatment
Number of subjects: 86
Study 23791261 — intervention group
Group type: EXPERIMENTAL
Intervention: Twisted File (TF) system
Number of subjects: 40
Study 23791261 — intervention group
Group type: COMPARATOR
Intervention: WaveOne (WO) system
Number of subjects: 40
Study 23791261 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TF and WO systems
Number of subjects: 40
Study 21391828 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer health workers (PHWs) providing care; specific dosage and duration not mentioned.
Number of subjects: 0
Study 21391828 — intervention group
Group type: COMPARATOR
Intervention: Control arm (conventional clinical staff); specific details not mentioned.
Number of subjects: 0
Study 17929164 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam + risperidone
Number of subjects: 40
Study 17929164 — intervention group
Group type: COMPARATOR
Intervention: Placebo + risperidone
Number of subjects: 40
Study 16673283 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Research Council Primary Thrombocythemia 1 trial (MRC PT‐1)
Number of subjects: 0
Study 12912807 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins C (500 mg/d) and E (400 IU/d) for 6 weeks
Number of subjects: 15
Study 12912807 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 15
Study 10924426 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoelectric alarms (58 homes)
Number of subjects: 123
Study 10924426 — intervention group
Group type: COMPARATOR
Intervention: Ionization alarms (65 homes)
Number of subjects: 123
Study 8669567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 63
Study 8669567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 1997932 — intervention group
Group type: EXPERIMENTAL
Intervention: MTC + L (metoclopramide 1 mg/kg or 0.5 mg/kg + lorazepam 2.5 mg) in HE and ME regimens respectively
Number of subjects: 100
Study 1997932 — intervention group
Group type: COMPARATOR
Intervention: ALZ + L (alizapride 3 mg/kg or 1.5 mg/kg + lorazepam 2.5 mg) in HE and ME regimens respectively
Number of subjects: 100
Study 1997932 — intervention group
Group type: EXPERIMENTAL
Intervention: MTC + L
Number of subjects: 100
Study 1997932 — intervention group
Group type: COMPARATOR
Intervention: ALZ + L
Number of subjects: 100
Study 6342461 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (5, 10, and 15 micrograms/kg)
Number of subjects: 71
Study 6342461 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (10 micrograms/kg)
Number of subjects: 71
Study 6342461 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 71
Study 6342461 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 71
Study 31404221 — intervention group
Group type: EXPERIMENTAL
Intervention: Open abdomen management with negative-peritoneal-pressure therapy (NPPT)
Number of subjects: 0
Study 31404221 — intervention group
Group type: COMPARATOR
Intervention: Formal abdominal closure
Number of subjects: 0
Study 30153752 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine plus placebo (0.5 mg/kg of ketamine)
Number of subjects: 30
Study 30153752 — intervention group
Group type: COMPARATOR
Intervention: Ketamine plus naltrexone (50 mg of naltrexone preceding ketamine)
Number of subjects: 30
Study 30153752 — intervention group
Group type: COMPARATOR
Intervention: Ketamine plus naltrexone
Number of subjects: 30
Study 27117852 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Number of subjects: 79
Study 27117852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid (Vitamin C)
Number of subjects: 79
Study 27117852 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC + Vitamin C
Number of subjects: 79
Study 27117852 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 79
Study 24755206 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led self-management education
Number of subjects: 404
Study 24755206 — intervention group
Group type: COMPARATOR
Intervention: Professionally delivered self-management education (seminar posts)
Number of subjects: 404
Study 24755206 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (peer-led and seminar posts)
Number of subjects: 404
Study 24755206 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with uncontrolled BP at baseline
Number of subjects: 404
Study 23158714 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lumen endotracheal tube (DLT)
Number of subjects: 120
Study 23158714 — intervention group
Group type: EXPERIMENTAL
Intervention: Univent blocker (UNI)
Number of subjects: 120
Study 23158714 — intervention group
Group type: EXPERIMENTAL
Intervention: Coopdech bronchial blocker (BB)
Number of subjects: 120
Study 19022621 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast echocardiography (CE) performed in the standing position
Number of subjects: 50
Study 19022621 — intervention group
Group type: COMPARATOR
Intervention: Contrast echocardiography (CE) performed in the supine position
Number of subjects: 50
Study 19022621 — intervention group
Group type: COMPARATOR
Intervention: Standard echocardiographic parameters
Number of subjects: 50
Study 17600655 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser (EVL) ablation of the great saphenous vein (980 nm)
Number of subjects: 121
Study 17600655 — intervention group
Group type: COMPARATOR
Intervention: High ligation and stripping (HL/S)
Number of subjects: 121
Study 15353973 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Vacc-4x
Number of subjects: 40
Study 15353973 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Vacc-4x
Number of subjects: 40
Study 15353973 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-A2 negative patients
Number of subjects: 40
Study 15353973 — intervention group
Group type: COMPARATOR
Intervention: HLA-A2 positive patients
Number of subjects: 40
Study 11593469 — intervention group
Group type: EXPERIMENTAL
Intervention: N(2)O/O(2)
Number of subjects: 10
Study 11593469 — intervention group
Group type: COMPARATOR
Intervention: O(2)
Number of subjects: 10
Study 9870830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multidisciplinary case management program
Number of subjects: 437
Study 9870830 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 437
Study 8066111 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching for 15 seconds
Number of subjects: 57
Study 8066111 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching for 30 seconds
Number of subjects: 57
Study 8066111 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching for 60 seconds
Number of subjects: 57
Study 8066111 — intervention group
Group type: COMPARATOR
Intervention: No stretching (Control)
Number of subjects: 57
Study 2543939 — intervention group
Group type: EXPERIMENTAL
Intervention: Müzli prepared from dry fruits and rough ground grain flakes of rich ballast material content
Number of subjects: 0
Study 2543939 — intervention group
Group type: COMPARATOR
Intervention: Traditional food of poor roughage content
Number of subjects: 0
Study 31005318 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaned by intake (successful-intake group)
Number of subjects: 64
Study 31005318 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaned by intake (early weaning)
Number of subjects: 64
Study 31005318 — intervention group
Group type: COMPARATOR
Intervention: Weaned by age
Number of subjects: 64
Study 31005318 — intervention group
Group type: COMPARATOR
Intervention: Weaned by intake (late weaning)
Number of subjects: 64
Study 27940188 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised psychosocial intervention (PSI) during OAT
Number of subjects: 368
Study 27940188 — intervention group
Group type: COMPARATOR
Intervention: Opioid agonist treatment-as-usual
Number of subjects: 368
Study 25370889 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg daily for 56 days
Number of subjects: 0
Study 25370889 — intervention group
Group type: COMPARATOR
Intervention: Placebo (days 1-28) followed by Armodafinil 150 mg daily (days 29-56)
Number of subjects: 0
Study 23818981 — intervention group
Group type: EXPERIMENTAL
Intervention: High viscosity (HV) semi‐solid meal
Number of subjects: 15
Study 23818981 — intervention group
Group type: COMPARATOR
Intervention: Standard viscosity (SV) semi‐solid meal
Number of subjects: 15
Study 22462234 — intervention group
Group type: EXPERIMENTAL
Intervention: Guo's Ma Qian Decoction, initial dose 0.4 g, increased by 0.05 g every two days, max 1.2 g/day.
Number of subjects: 114
Study 22462234 — intervention group
Group type: COMPARATOR
Intervention: Decoction placebo (control group).
Number of subjects: 114
Study 22462234 — intervention group
Group type: EXPERIMENTAL
Intervention: Guo's Ma Qian Decoction, blood strychnine and brucine levels.
Number of subjects: 114
Study 19436136 — intervention group
Group type: EXPERIMENTAL
Intervention: VKORC1 rs8050894 GG homozygotes
Number of subjects: 416
Study 19436136 — intervention group
Group type: EXPERIMENTAL
Intervention: VKORC1 rs7294 AA or AG carriers
Number of subjects: 416
Study 19436136 — intervention group
Group type: EXPERIMENTAL
Intervention: GGCX rs10187424 and rs7568458 heterozygous carriers
Number of subjects: 416
Study 16446336 — intervention group
Group type: EXPERIMENTAL
Intervention: CVI fluorouracil (FU) 225 mg/m2 per day, 7 days per week, plus pelvic hyperfractionated radiation 55.2 to 60 Gy at 1.2 Gy bid (arm 1)
Number of subjects: 106
Study 16446336 — intervention group
Group type: EXPERIMENTAL
Intervention: CVI FU 225 mg/m2 per day Monday to Friday, 120 hours per week plus irinotecan 50 mg/m2 once weekly for 4 weeks plus pelvic radiation therapy 50.4 to 54 Gy at 1.8 Gy per day (arm 2)
Number of subjects: 106
Study 12844212 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (supervised aerobic, weight‐bearing and weight‐lifting exercise, three times per week) with calcium supplementation (800 mg daily)
Number of subjects: 320
Study 12844212 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (with calcium supplementation)
Number of subjects: 320
Study 12844212 — intervention group
Group type: COMPARATOR
Intervention: No exercise (with calcium supplementation)
Number of subjects: 320
Study 10993791 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-rate atrial pacing at multiple cycle lengths (CLs)
Number of subjects: 24
Study 10993791 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing with isoproterenol
Number of subjects: 24
Study 10993791 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher heart rate (HR)
Number of subjects: 24
Study 10993791 — intervention group
Group type: COMPARATOR
Intervention: Moderate elevation of HR
Number of subjects: 24
Study 8996468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap (40-200 mg/day)
Number of subjects: 198
Study 8996468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 1282537 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (traditional and low-dose regimens)
Number of subjects: 855
Study 1282537 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (three groups)
Number of subjects: 855
Study 1282537 — intervention group
Group type: COMPARATOR
Intervention: Dextran
Number of subjects: 855
Study 1282537 — intervention group
Group type: COMPARATOR
Intervention: External pneumatic compression
Number of subjects: 855
Study 1282537 — intervention group
Group type: COMPARATOR
Intervention: Dextran combined with external pneumatic compression
Number of subjects: 855
Study 3905183 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto‐Syringe AS 6C (basal rate in pulses every 2‐10 min)
Number of subjects: 6
Study 3905183 — intervention group
Group type: COMPARATOR
Intervention: Medix Syringe Driver 209 (basal rate in pulses every 15‐60 min)
Number of subjects: 6
Study 30462837 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Working Memory (WM) training for 5 weeks
Number of subjects: 50
Study 30462837 — intervention group
Group type: COMPARATOR
Intervention: Control training
Number of subjects: 50
Study 30462837 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Working Memory (WM) training
Number of subjects: 50
Study 31034598 — intervention group
Group type: EXPERIMENTAL
Intervention: ontuxizumab (8 mg/kg) plus gemcitabine and docetaxel (G/D)
Number of subjects: 209
Study 31034598 — intervention group
Group type: COMPARATOR
Intervention: placebo plus gemcitabine and docetaxel (G/D)
Number of subjects: 209
Study 27823901 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric-concentric training combined with isometric contraction
Number of subjects: 34
Study 27823901 — intervention group
Group type: COMPARATOR
Intervention: Eccentric training
Number of subjects: 34
Study 27823901 — intervention group
Group type: COMPARATOR
Intervention: Eccentric-concentric training
Number of subjects: 34
Study 24947675 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone orodispersible tablet (OOT) 20 mg
Number of subjects: 12
Study 24947675 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol orodispersible tablet (POT) 500 mg
Number of subjects: 12
Study 23375525 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g/d of ω‐3 PUFA
Number of subjects: 12
Study 23375525 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 g/d of ω‐3 PUFA
Number of subjects: 12
Study 23375525 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study 21410828 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated Estrogen (CEE) 0.625 mg/day
Number of subjects: 75
Study 21410828 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated Estrogen (CEE) 0.625 mg/day plus Medroxyprogesterone Acetate (MPA) 2.5 mg/day
Number of subjects: 75
Study 19270449 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/kg intravenous mesna administered predialysis for 1 week
Number of subjects: 0
Study 19270449 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered predialysis for 1 week
Number of subjects: 0
Study 19270449 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/kg intravenous mesna administered predialysis for 4 weeks
Number of subjects: 0
Study 19270449 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered predialysis for 4 weeks
Number of subjects: 0
Study 17416878 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic care model approach to injury prevention; Intervention details: Focused counseling from a physician and health assistant, educational handouts, phone follow-up, access to free safety devices and automobile restraint evaluations.
Number of subjects: 27
Study 17416878 — intervention group
Group type: COMPARATOR
Intervention: Standard anticipatory guidance; Control group: Yes
Number of subjects: 27
Study 15254053 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 1: Cisplatin 10 mg/m² daily and fluorouracil (FU) 400 mg/m² continuous infusion (CI) daily for the final 10 days of treatment
Number of subjects: 231
Study 15254053 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 2: Hydroxyurea 1 g every 12 hours and FU 800 mg/m²/d CI delivered with each fraction of radiation
Number of subjects: 231
Study 15254053 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 3: Weekly paclitaxel 30 mg/m² and cisplatin 20 mg/m²
Number of subjects: 231
Study 12027068 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol HFA (180 microg ex-actuator)
Number of subjects: 24
Study 12027068 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol CFC (180 microg ex-actuator)
Number of subjects: 24
Study 12027068 — intervention group
Group type: COMPARATOR
Intervention: Placebo HFA
Number of subjects: 24
Study 9824345 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound evaluation of splanchnic haemodynamics in Crohn's disease
Number of subjects: 79
Study 9824345 — intervention group
Group type: COMPARATOR
Intervention: Doppler ultrasound evaluation of splanchnic haemodynamics in controls
Number of subjects: 79
Study 9824345 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise multiple regression analysis
Number of subjects: 79
Study 9824345 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of splanchnic haemodynamics
Number of subjects: 79
Study 7973478 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg triamcinolone hexacetonide (TA)
Number of subjects: 31
Study 7973478 — intervention group
Group type: COMPARATOR
Intervention: 330 mg sodium morrhuate (SM)
Number of subjects: 31
Study 2532184 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (150 micrograms/day for 4 weeks)
Number of subjects: 20
Study 31377306 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Pilates training
Number of subjects: 42
Study 31377306 — intervention group
Group type: COMPARATOR
Intervention: Home exercise training
Number of subjects: 42
Study 30823900 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visits
Number of subjects: 426
Study 30823900 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle strengthening exercises
Number of subjects: 426
Study 30823900 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality indicators adherence
Number of subjects: 426
Study 27810290 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART score
Number of subjects: 1748
Study 27810290 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE score
Number of subjects: 1748
Study 27810290 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI score
Number of subjects: 1748
Study 26297701 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed low-resistance training (LOW+, 1 × 60 repetitions at 20% 1 RM followed by 1 × 10-20 repetitions at 40% 1 RM)
Number of subjects: 56
Study 26297701 — intervention group
Group type: COMPARATOR
Intervention: High-resistance training (HIGH, 2 × 10-15 repetitions at 80% 1 RM)
Number of subjects: 56
Study 26297701 — intervention group
Group type: COMPARATOR
Intervention: Low-resistance training (LOW, 1 × 80-100 repetitions at 20% 1 RM)
Number of subjects: 56
Study 23833916 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% w/w stannous fluoride dentifrice
Number of subjects: 118
Study 23833916 — intervention group
Group type: COMPARATOR
Intervention: Negative control dentifrice (1,000 ppm fluoride as sodium monofluorophosphate)
Number of subjects: 118
Study 21354234 — intervention group
Group type: EXPERIMENTAL
Intervention: Danoprevir/r (100/100mg twice daily) plus peginterferon alfa-2a (40KD)/ribavirin
Number of subjects: 30
Study 21354234 — intervention group
Group type: EXPERIMENTAL
Intervention: Danoprevir/r (200/100mg once daily) plus peginterferon alfa-2a (40KD)/ribavirin
Number of subjects: 30
Study 21354234 — intervention group
Group type: EXPERIMENTAL
Intervention: Danoprevir/r (200/100mg twice daily) plus peginterferon alfa-2a (40KD)/ribavirin
Number of subjects: 30
Study 21354234 — intervention group
Group type: COMPARATOR
Intervention: Placebo/r plus peginterferon alfa-2a (40KD)/ribavirin
Number of subjects: 30
Study 18506466 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid alginate suspension (Gaviscon Advance) 10 ml four times daily after meals and at bedtime
Number of subjects: 49
Study 18506466 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 49
Study 16290918 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-support tools
Number of subjects: 0
Study 16290918 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15330693 — intervention group
Group type: EXPERIMENTAL
Intervention: Active home stretching
Number of subjects: 33
Study 15330693 — intervention group
Group type: COMPARATOR
Intervention: Passive home stretching
Number of subjects: 33
Study 10768064 — intervention group
Group type: EXPERIMENTAL
Intervention: ticarcillin/clavulanate (3.1 g every 4 or 6 hours)
Number of subjects: 11
Study 10768064 — intervention group
Group type: EXPERIMENTAL
Intervention: ticarcillin/clavulanate with amikacin (when pneumonia was due to Pseudomonas aeruginosa)
Number of subjects: 11
Study 10768064 — intervention group
Group type: EXPERIMENTAL
Intervention: ticarcillin/clavulanate
Number of subjects: 11
Study 9260072 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate, informative monetary consequence (MI) under moderate dose of alcohol (0.62 g/kg)
Number of subjects: 40
Study 9260072 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed, uninformative monetary consequence (M) under moderate dose of alcohol (0.62 g/kg)
Number of subjects: 40
Study 9260072 — intervention group
Group type: EXPERIMENTAL
Intervention: No consequence (N) under moderate dose of alcohol (0.62 g/kg)
Number of subjects: 40
Study 9260072 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) performed the task without alcohol or any consequence
Number of subjects: 40
Study 7678061 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (2 x 10(6) KIU in the cardiopulmonary bypass priming solution)
Number of subjects: 30
Study 7678061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7678061 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin
Number of subjects: 30
Study 7073920 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.30 mg kg‐1 i.v.)
Number of subjects: 194
Study 7073920 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 194
Study 31260526 — intervention group
Group type: EXPERIMENTAL
Intervention: AFEX-treated wheat straw
Number of subjects: 16
Study 31260526 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymes (500 µg of protein/g straw DM)
Number of subjects: 16
Study 31260526 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymes
Number of subjects: 16
Study 31260526 — intervention group
Group type: COMPARATOR
Intervention: Untreated wheat straw
Number of subjects: 16